Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
20
CLSD Quote, Financials, Valuation and Earnings
Last price:
$0.87
Seasonality move
:
14.23%
Day range:
$0.80 - $0.93
52-week range:
$0.80 - $2.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.98x
P/B ratio:
--
Volume:
942.8K
Avg. volume:
286.9K
1-year change:
-12.77%
Market cap:
$66.2M
Revenue:
$8.2M
EPS (TTM):
-$0.45
Analysts' Opinion
-
Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Clearside Biomedical has an estimated upside of 587.84% from its current price of $0.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.87.
Fair Value
-
According to the consensus of 0 analysts, Clearside Biomedical has 587.84% upside to fair value with a price target of -- per share.
CLSD vs. S&P 500
-
Over the past 5 trading days, Clearside Biomedical has underperformed the S&P 500 by -12.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Clearside Biomedical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Clearside Biomedical has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Clearside Biomedical reported revenues of $1M.
Earnings Growth
-
Clearside Biomedical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Clearside Biomedical reported earnings per share of -$0.10.
Enterprise value:
42.6M
EV / Invested capital:
-1.22x
Price / LTM sales:
7.98x
EV / EBIT:
--
EV / Revenue:
5.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-92.84%
Net Income Margin (TTM):
-413.83%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-571.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $26.7M | $2.2M | $7.7M | $859K | $1M | |
| Gross Profit | -- | -- | -- | $717K | $1M | |
| Operating Income | -$3.5M | -$30M | -$24.6M | -$7.1M | -$5.9M | |
| EBITDA | -$3.1M | -$28.1M | -$22.2M | -$6.6M | -$5.2M | |
| Diluted EPS | -$0.08 | -$0.61 | -$0.45 | -$0.15 | -$0.10 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16M | $26.5M | $54.9M | $30.8M | $25.1M | |
| Total Assets | $17.4M | $27.4M | $55.7M | $34.4M | $29.2M | |
| Current Liabilities | $8.2M | $9.2M | $5.2M | $5.8M | $5.6M | |
| Total Liabilities | $9.3M | $9.5M | $37.1M | $47.3M | $64M | |
| Total Equity | $8.1M | $17.8M | $18.5M | -$12.8M | -$34.8M | |
| Total Debt | $991K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.7M | -$24.2M | -$18.9M | -$6.1M | -$5.9M | |
| Cash From Investing | -$155K | -$1.7M | -$10.1M | -$445K | $1.5M | |
| Cash From Financing | $30.9M | $1.2M | $14.1M | $317K | $14K | |
| Free Cash Flow | -$2.9M | -$26M | -$19.6M | -$6.5M | -$6M | |
CLSD
Sector
Market Cap
$66.2M
$44.6M
Price % of 52-Week High
41.15%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-15.86%
-0.68%
1-Year Price Total Return
-12.77%
-29.09%
Beta (5-Year)
2.292
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.98
200-day SMA
Sell
Level
$1.22
Bollinger Bands (100)
Sell
Level
0.98 - 1.24
Chaikin Money Flow
Sell
Level
-132.2M
20-day SMA
Sell
Level
$1.02
Relative Strength Index (RSI14)
Sell
Level
29.02
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-76.1538
50-day SMA
Sell
Level
$1.07
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
213M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-13.503)
Sell
CA Score
(Annual)
Level (-5.4148)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (9.9222)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Stock Forecast FAQ
In the current month, CLSD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLSD average analyst price target in the past 3 months is --.
-
Where Will Clearside Biomedical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Clearside Biomedical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Clearside Biomedical?
Analysts are divided on their view about Clearside Biomedical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Clearside Biomedical is a Sell and believe this share price will drop from its current level to --.
-
What Is Clearside Biomedical's Price Target?
The price target for Clearside Biomedical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLSD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Clearside Biomedical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLSD?
You can purchase shares of Clearside Biomedical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Clearside Biomedical shares.
-
What Is The Clearside Biomedical Share Price Today?
Clearside Biomedical was last trading at $0.87 per share. This represents the most recent stock quote for Clearside Biomedical. Yesterday, Clearside Biomedical closed at $0.87 per share.
-
How To Buy Clearside Biomedical Stock Online?
In order to purchase Clearside Biomedical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
